In this episode, Courtney will update you on papers published in September 2020 on the Disease Mechanisms of ApoE. You will hear about cognitive impacts of ApoE, ethnic variability in ApoE, Neuroimaging of ApoE isoforms, and even some additional genetic implications of ApoE.

List of Sections:

Impact on Cognitive Abilities: 3.00

Ethnic Variability Behind ApoE Isoforms: 14.17

Neuroimaging with ApoE Isoforms: 18.20

Genetic Mechanisms of ApoE: 24.07

If you can’t quite decide which episode to listen to, maybe give this one a try. We’re covering preclinical models of AD as it pertains to mitochondria, autophagy, metabolism, behaviour, and much much more. Join Anusha so she doesn’t have to explore all these exciting papers all by herself!

List of Sections:

Mitochondria: 1.31

Autophagy/Metabolism: 5.34

Behaviour: 12.12

Other: 23.07

This episode is the second half of a two part series covering papers published in September 2020 on treatment approaches with multiple targets for Alzheimer’s disease. For part 1 of this series, check out episode 74! In this part, we’ll take a look at papers targeting many different AD processes, including oxidative stress, cholinesterase activity, and amyloid beta formation. The final paper in this episode will cover a new study using gene therapy to target AD.

You'll hear about how mechanisms of oxidative stress, autophagy and the gut microbiome may contribute to AD pathology, as Abdullah updates you on the new papers from September 2020 on these topics. Enjoy!

In this episode, Judy goes over papers published in September 2020 that focus on sex differences in Alzheimer’s disease. We also cover a few papers that did not quite fit into our other genetics-themed episodes, including AD-related stigma, lewy body dementia and overlapping risk factors of AD and Parkinson’s disease. Tune in to learn more!

Naila is back to round off the non-genetic risk factors for September, with 6 papers on a variety of potential comorbidities, and 7 more on epidemiological studies and the interaction of various modifiable risk factors. We cover a lot of ground and geographic locations this episode, so buckle in for a solid - but hopefully riveting - half hour of information!

In this episode, Alex will be covering papers published in September 2020 within the category of novel drug development, that focus on multi-targeted approaches to Alzheimer’s disease treatment. We’ll take a look at papers targeting many different AD processes, including oxidative stress, cholinesterase activity, and amyloid beta formation. Part 2 will be coming out shortly!

In this episode, Naila goes through 13 papers that explore how benzodiazepine and anticholinergic drug use affect individuals with dementia, whether exposure to certain air pollutants increase the risk of AD, and how cognitive reserve - whether in the form of occupation, bilingualism or education - may protect against cognitive decline. Enjoy!

What is it about neurotransmission that is so difficult to regulate in Alzheimer's? Anusha will tell you in this episode, so tune in if you're interested in the role of cholinergic and glutamatergic transmission, or the role of the hippocampus in AD.

This episode, hosted by Jacques, explores many facets of amyloid-beta mediated toxicity. First, we run through the structure-toxicity relationships of mutant amyloid-beta. Second, we investigate the interaction of amyloid-beta oligomers with membranes and their effect on vesicular trafficking and endocytosis. And lastly, we finish the episode on insights into the effects of amyloid-beta on neurotransmitter systems in AD.